Observational Study to Evaluate Allogeneic HSCT Outcomes for Cerebral Adrenoleukodystrophy (CALD)

Cerebral Adrenoleukodystrophy (CALD) Clinical Trial

Official title:
A Prospective and Retrospective Data Collection Study to Evaluate Outcomes in Males ≤17 Years of Age Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Cerebral Adrenoleukodystrophy

Status Terminated

Clinical Trial Summary

Study ALD-103 will be a multi-site, global, prospective and retrospective data collection study that is designed to evaluate outcomes of allo-HSCT in male subjects with CALD ≤17 years of age.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Adrenoleukodystrophy
Adrenoleukodystrophy (ALD)
Cerebral Adrenoleukodystrophy (CALD)
X-Linked Adrenoleukodystrophy (X-ALD)

Clinical Trial Details

NCT number	NCT02204904
Study type	Observational
Source	bluebird bio
Contact
Status	Terminated
Phase
Start date	April 2015
Completion date	December 6, 2019

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06224413` - A Study of Participants With Cerebral Adrenoleukodystrophy (CALD) Treated With Elivaldogene Autotemcel
Recruiting	`NCT05819866` - A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy	Phase 3
Completed	`NCT03852498` - A Clinical Study to Assess the Efficacy and Safety of Gene Therapy for the Treatment of Cerebral Adrenoleukodystrophy (CALD)	Phase 3
Active, not recruiting	`NCT02698579` - Long-term Follow-up of Participants With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product
Completed	`NCT01896102` - A Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Cerebral Adrenoleukodystrophy (CALD)	Phase 2/Phase 3